NEW YORK (GenomeWeb) – Becton Dickinson announced this week that it has agreed to sell 50.1 percent of its respiratory solutions business to funds advised by global private equity firm Apax Partners. The new company will include all business lines within BD's respiratory solutions business including respiratory diagnostics, and will have estimated annual revenue of approximately $900 million. BD will retain 49.9 percent of the company. The transaction values the entire business today at nearly $500 million, and is expected to close in late fiscal year 2016 or early fiscal year 2017.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.